Skip to main content
All lobbying filings

ALLIANCE FOR AGING RESEARCH

Lobbying for ALLIANCE FOR AGING RESEARCH

 Filing Q1 report
Reporting period
1st Quarter 2026
Jan 1 - Mar 31 · Posted Apr 20, 2026
Expenses
$60,000.00
What this organization spent lobbying with its own staff. Reported using A: the three LDA methods count different costs, so an expenses figure is not comparable across filers that used different ones.
Client based in
District of Columbia

Official filing document

 Lobbyists on this filing 1
  • SCOTT FREY New on this filing
    Previously held: Deputy Commissioner for Legislation and Congressional Affairs -- SSA, Chief of Staff -- SSA, Senior Strategic Advisor -- Office of National Drug Control Policy

A "covered position" is a government job the lobbyist held in the 20 years before registering, which the law requires them to name. See the revolving door for former members of Congress across all filings.

 Government bodies contacted 4

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when. Each name opens every filing that named the same body.

 Bills named in this filing 5
 Lobbying activity 3
Health Issues

-Alzheimer's Screening & Prevention Act (ASAP) H.R. 6130/ S. 3267 -Lowering Costs for Caregivers Act (S. 1565/H.R. 138) -Federal vaccine messaging -Impacts of IRA on Older Americans -National Institutes of Health advance funding of multi-year research grants

Medicare/Medicaid

-Implementation of Medicare Part D beneficiary affordability provisions -Nursing home quality measures -Implementation of the Medicare Direct Negotiation Program and its impact on older adults -Utilization management reform in Medicare -Increasing Medication Access for Seniors Act (H.R.6401)

Budget/Appropriations

-FY27 report language for the Food and Drug Administration on antipsychotics black box warning -FY27 report language for the Medicare Program antipsychotics measure -FY27 report language for the Medicare Prescription Payment Plan -FY27 report language for utilization management reform in the Medicare program -FY27 medical research funding -FY27 funding for FDA's Neurology Drug Program

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.

Report a problem